Filing summary
Company: Unicycive Therapeutics, Inc. Filing: Form 8-K, reporting events dated September 28–29, 2026.
Business context and material developments
- On September 28, the company appointed Meredith S. Manning as an independent director, effective October 1, 2026.
- Manning will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees and chair the Nominating and Corporate Governance Committee. The filing cites her more than 25 years of biopharmaceutical experience, including commercial leadership and product launches.
- On September 29, the company announced resubmission of a New Drug Application for Oxylanthanum Carbonate. The 8-K references a press release as Exhibit 99.1, but its substantive details are not included in the provided filing text.
Financial results and outlook
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial results. It provides no financial guidance or outlook.
Risks, contingencies, and unusual items
The filing does not describe specific financial contingencies or quantify risks related to the NDA resubmission. It states that the company is not aware of any reportable transaction involving Manning or her immediate family and the company.
Key facts for investors to verify
- Review the referenced September 29 press release for the NDA resubmission’s details, timing, and any regulatory context.
- Confirm the director appointment and committee assignments took effect as stated on October 1, 2026.
- Consult the company’s financial filings for current financial performance, liquidity, and runway, which are not addressed here.